A diaryl pyrimidine compound containing an ether bond and its preparation method and application
By introducing ether bonds into diarylpyrimidine compounds, a novel anti-HIV-1 inhibitor was developed against highly conserved amino acid residues in primer clamping regions, solving the existing NNRTIs in drug-resistant strains and toxic side effects. The problem is that effective inhibition and low cytotoxicity of HIV-1 have been achieved, and it has potential application value for anti-AIDS drugs.
Patent Information
- Application Number
- CN202211149680.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-09-21
AI Technical Summary
Existing non-nucleoside reverse transcriptase inhibitors (NNRTIs) have problems with drug-resistant strains, toxic side effects and poor pharmacokinetic properties in anti-AIDS treatment, which limits their application, especially for highly conservative primer clamp areas. The targeted treatment of amino acid residues is not effective.
A class of diarylpyrimidine compounds containing ether bonds was designed to enhance the effect of using ether bonds to the left-wing structure to generate new forces with highly conserved amino acid residues as a new anti-HIV-1 inhibitor to enhance the The inhibitory effect of HIV-1 reverse transcriptase.
This compound exhibits significant inhibitory activity on wild-type and mutant HIV-1 at the cellular level, especially on K103N and E138K mutant strains, with low cytotoxicity and high selectivity, which is better than the existing ones Positive drugs have the value of further research and development.
Smart Images

Figure CN115490642B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to a diaryl pyrimidine compound containing an ether bond. The present invention also relates to a preparation method of such derivatives and their application in preparing drugs for treating human immunodeficiency virus (HIV). Background Art
[0002] AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is a common clinical treatment for AIDS. Highly Active Antiretroviral Therapy (HAART) is currently used. As an important component of HAART, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have become a hot topic in the research of anti-AIDS drugs due to their excellent antiviral efficacy, high specificity, and low cytotoxicity. However, the emergence of multiple drug-resistant strains, toxic side effects, and other problems in clinical treatment have limited their application. The development of highly efficient, low-toxic, and anti-resistant NNRTIs is still a major scientific research task in the field of anti-AIDS drug research.
[0003] Diarylpyrimidines (DAPYs) inhibitors are a class of NNRTIs with good structural flexibility and can effectively inhibit wild-type and mutant HIV-1 strains. The marketed drugs rilpivirine (RPV) and etravirine (ETR) are important representatives of DAPY inhibitors. The crystal complex structure of their DAPY inhibitors with HIV-1 reverse transcriptase shows that the left-wing cyanovinyl or cyano group is located in the hydrophobic channel, and the extensive hydrophobic interaction with the surrounding amino acids plays an important role in maintaining activity. However, the emergence of drug-resistant strains in clinical treatment, poor pharmacokinetic properties and high cytotoxicity have limited their use. The primer clamp region (β12 and β13 sheets) near the hydrophobic channel is responsible for positioning the 3'-OH of the primer at the polymerase catalytic site, which plays an important role in RT catalytic activity. This region contains the amino acid residues F227, W229, and L234 in NNIBP, and W229 is highly conserved. Targeting highly conserved amino acid residues is of great significance for the discovery of new and highly effective anti-resistance compounds. Therefore, targeting the primer clamp region, using the structure-based drug design concept, an ether bond was introduced into the left-wing structure of the DAPY compound, and a series of diaryl pyrimidine derivatives were designed by replacing it with different substituted aromatic heterocycles in the hope that the newly introduced group could produce new interactions with the highly conserved amino acids in this region.
[0004] Summary of the invention
[0005] The purpose of the present invention is to provide a diaryl pyrimidine compound containing an ether bond and a preparation method thereof. The present invention also provides the screening results of the anti-HIV-1 activity of the compound and the application of the compound in the preparation of antiviral drugs.
[0006] The technical solution of the present invention is as follows:
[0007] 1. Diaryl pyrimidine compounds containing ether bonds
[0008] The present invention provides a diaryl pyrimidine compound containing an ether bond or a pharmaceutically acceptable salt thereof, having a structure shown in general formula I:
[0009]
[0010] In the above general formula:
[0011] R1, R2 are independently: H, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, C 2- C6 alkenyl, trifluoromethyl, amino, hydroxyl or cyanovinyl;
[0012] R3 is a substituted or unsubstituted benzene ring, a substituted or unsubstituted naphthalene ring, a substituted or unsubstituted six-membered heterocycle, a substituted or unsubstituted five-membered heterocycle, a substituted or unsubstituted six-membered and five-membered heterocycle, a substituted or unsubstituted six-membered and six-membered heterocycle, a substituted or unsubstituted five-membered and five-membered heterocycle, a substituted or unsubstituted benzo five-membered heterocycle, or a substituted or unsubstituted benzo six-membered heterocycle, and the substituent is selected from methyl, ethyl, methoxy, nitro, cyano, amino, BOC-amino, carboxyl, trifluoromethyl, halogen, hydroxyl or hydroxymethyl.
[0013] According to the preferred embodiment of the present invention,
[0014] R3 is a substituted or unsubstituted benzene ring, a substituted or unsubstituted pyridine ring. The substituent is selected from methoxy, nitro, cyano, amino, BOC-amino, F, Cl, Br or hydroxymethyl.
[0015] According to the present invention, the ether-bonded diaryl pyrimidine compound represented by the general formula I is one of the following compounds:
[0016]
[0017]
[0018]
[0019] The "pharmaceutically acceptable salt" described in the present invention refers to a salt of a compound that is suitable for contact with human or lower animal tissues without undue toxicity, irritation, and allergic reaction within a reliable pharmaceutical evaluation range, has a fairly reasonable benefit / risk ratio, is usually water or oil soluble or dispersible, and can be effectively used for its intended purpose. It includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts, which can be used for the intended purpose and are compatible with the chemical properties of the compound of formula I. For a list of suitable salts, see SM Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19.
[0020] 2. Preparation method of diaryl pyrimidine compounds containing ether bonds
[0021] The synthesis process of the I series compounds is as follows: 2-methylthio-4-pyrimidone is used as a starting material to undergo a melt reaction with 4-aminobenzonitrile to obtain intermediate 2; phosphorus oxychloride is used as a solvent and a reaction reagent to react with 2 to generate intermediate 3; 3 undergoes a substitution reaction with differently substituted 4-hydroxybenzaldehyde to obtain intermediate 4; 4 undergoes a reduction reaction with sodium borohydride to obtain intermediate 5; 5 is brominated with phosphorus tribromide to obtain key intermediate 6; under alkaline conditions, 6 undergoes a nucleophilic substitution reaction with differently substituted phenolic compounds to obtain the target compound I;
[0022] The synthetic route is as follows:
[0023]
[0024] Reagents and conditions: (i) 4-aminobenzonitrile, 180°C; (ii) phosphorus oxychloride, 105°C; (iii) Potassium carbonate, N,N-dimethylformamide, 100℃; (iv) sodium borohydride, methanol, 0℃~rt; (v) phosphorus tribromide, dichloromethane, 0℃~rt; (vi) substituted phenolic compounds, potassium hydroxide, potassium iodide, acetonitrile, 80℃;
[0025] Wherein, R1, R2, and R3 are as described in Formula I.
[0026] The substituted phenolic compound is: substituted or unsubstituted phenol, substituted or unsubstituted hydroxypyridine, and the substituent is selected from methoxy, nitro, cyano, amino, BOC-amino, F, Cl, Br or hydroxymethyl.
[0027] The room temperature described in the present invention is 20-30°C.
[0028] 3. Activity and application of diaryl pyrimidine compounds containing ether bonds against HIV-1 wild-type and mutant strains
[0029] The diaryl pyrimidine derivatives synthesized according to the above method were screened for activity against wild-type HIV-1 (IIII), single mutants L100I, K103N, Y181C, Y188L, E138K and double mutants F227L / V106A, RES056 (K103N / Y181C) at the cellular level, with zidovudine (AZT), nevirapine (NVP), efavirenz (EFV), and etravirine (ETR) as positive controls. The results are shown in Tables 1 and 2. The results show that all compounds exhibited single nanomolar to several hundred nanomolar activities against wild-type HIV-1, among which compound I-2 (EC 50 =7.6nM) has the most prominent activity, which is better than the positive drug AZT (EC 50 =0.127 μM) and NVP (EC 50 =0.023 μM), it is worth noting that I-2 (CC 50 >279.33μM, SI>36610.9) showed low cytotoxicity and high selectivity. For the tested HIV-1 mutants, most compounds showed inhibitory activity of tens to hundreds of nanomoles against K103N and E138K. Therefore, this type of diaryl pyrimidine compound has the value of further research and development and can be used as a lead compound against HIV-1.
[0030] The ether-bonded diaryl pyrimidine compounds of the present invention can be used as non-nucleoside HIV-1 inhibitors, and specifically, can be used as HIV-1 inhibitors for preparing anti-AIDS drugs.
[0031] An anti-HIV-1 pharmaceutical composition comprises the diaryl pyrimidine compound containing a trans double bond of the present invention and one or more pharmaceutically acceptable carriers or excipients.
[0032] The present invention provides a novel ether-bonded diaryl pyrimidine compound and a preparation method thereof. The present invention also provides the anti-HIV-1 activity screening results of the compound and its first application in the antiviral field. Experiments have shown that the ether-bonded diaryl pyrimidine compound of the present invention can be used as an HIV-1 inhibitor. Specifically, it can be used as an HIV-1 inhibitor for the preparation of anti-AIDS drugs. DETAILED DESCRIPTION
[0033] The following examples are provided to help understand the present invention, but they cannot limit the content of the present invention.
[0034] The synthetic route involved in the embodiment is as follows:
[0035]
[0036] Example 1: Preparation of 4-((4-(4-formyl-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (Intermediate 4).
[0037] Weigh the starting materials 2-(methylthio)pyrimidin-4(3H)-one (4.97 g, 35.00 mmol) and 4-aminobenzonitrile (4.96 g, 42.00 mmol), place the two in a 250 mL round-bottom flask and mix them evenly. Under the protection of nitrogen (N2), slowly heat to 180 ° C and melt react for 8 hours. After the reaction is cooled to 80 ° C, 50 ml of acetonitrile is added to the reaction bottle and ultrasonic treatment is performed. The turbid liquid obtained by ultrasonication is filtered, and the filter cake is washed with acetonitrile until TLC detects that there is no raw material residue. Dry the filter cake and collect it to obtain a pale yellow solid crude product, namely intermediate 2. Yield: 62%; ESI-MS: m / z 213.3 [M+H] + ,C 11 H8N4O(212.12).
[0038] Weigh the intermediate 2 (3.00 g, 14.14 mmol) and dissolve it in 20 mL of phosphorus oxychloride. Heat and reflux at 105 ° C for 2 h. After the reaction is complete by TLC, slowly add the reaction solution dropwise to 300 mL of ice-water mixture, and a yellow precipitate is generated. Stir for 0.5 h and filter. Dry the filter cake to obtain the intermediate 3. Yield: 65%. 1H NMR (400 MHz, DMSO-d6) δ10.58 (s, 1H, NH), 8.55 (d, J = 5.2 Hz, 1H, C6-pyrimidine-H), 7.87 (dd, 4H, Ph-H), 7.13 (d, J = 5.2 Hz, 1H, C6-pyrimidine-H); ESI-MS: m / z 231.2 [M+H] + ,C 11 H7ClN4(230.04).
[0039] Weigh intermediate 3 (3.00 g, 13.04 mmol), 3,5-dimethyl-4-hydroxybenzaldehyde (2.35 g, 15.65 mmol), anhydrous potassium carbonate (3.60 g, 26.08 mmol) and dissolve in 5 mL DMF solvent, heat to 100 ° C and react for 10 h. After the reaction is complete as detected by TLC, the reaction solution is cooled to room temperature and 30 mL of saturated sodium chloride solution is added to produce a brown solid. Filter and dry to obtain intermediate 4. Yield: 61%.
[0040] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.13(s,1H,-CHO),10.03(s,1H,NH),8.50(d,J=5.6Hz,1H,C6-pyrimidine-H),7.80(s,2H,Ph-H),7.56(d,J =8.6Hz,2H,Ph-H),7.44(d,J=8.7Hz,2H,Ph-H),6.71(d,J=5.6Hz,1H,C5-pyrimidine-H),2.17(s,6H,2×CH3).ESI-MS:m / z345.4[M+H] + ,C 20 H 16 N4O2(344.13).
[0041] Example 2: Preparation of 4-((4-(4-(hydroxymethyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (Intermediate 5).
[0042] Weigh 4 (1.00 g, 2.91 mmol) and dissolve it in 50 mL of methanol solution. Then, sodium borohydride (0.10 g, 2.91 mmol) was slowly added to the reaction solution in batches under ice bath conditions and reacted for 0.5 h. The reaction was moved to room temperature and continued to react for 4 h. After TLC detection, the solvent was evaporated under reduced pressure, and then 20 mL of saturated salt water solution was added to the residual substrate, extracted with ethyl acetate (3×20 mL), and the organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated. Intermediate 5 was separated by rapid column chromatography as a white solid. Yield: 45.3%.
[0043] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.11(s,1H,NH),8.44(d,J=5.6Hz,1H,C6-pyrimidine-H),7.59(d,J=8.7Hz,2H,Ph-H),7.50(d,J=8.8Hz,2H,Ph-H),7. 15(s,2H,Ph-H),6.60(d,J=5.6Hz,1H,C5-pyrimidine-H),5.25(t,J=5.6Hz,1H,OH),4.52(d,J=5.6Hz,2H,CH2),2.07(s,6H,2×CH3).ESI-MS:m / z 347.3[M+H] + ,C 20 H 18 N4O2(346.14).
[0044] Example 3: Preparation of 4-((4-(4-(bromomethyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (Intermediate 6).
[0045] Weigh the intermediate 5 (1.00 g, 2.88 mmol) and dissolve it in 10 mL of dichloromethane solution. Then, under ice bath conditions, dissolve phosphorus tribromide (0.33 mL, 3.46 mmol) in dichloromethane and add it dropwise to the reaction solution for 2 h. Move to room temperature and continue the reaction for 2 h. After the reaction is complete by TLC detection, evaporate the solvent under reduced pressure, then add 20 mL of saturated salt water solution to the residual substrate, extract with ethyl acetate (3×20 mL), collect the organic phase, dry with anhydrous sodium sulfate, filter and concentrate. Rapid column chromatography separation gives the intermediate 6 as a white solid. Yield: 51%.
[0046] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.14(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),7.56(d,J=8.6Hz,2H,Ph-H),7.52(d,J=8.2Hz,2 H,Ph-H),7.32(s,2H,Ph-H),6.66(d,J=5.6Hz,1H,C5-pyrimidine-H),4.79(d,J=18.3Hz,2H,CH2),2.07(s,6H,2×CH3).ESI-MS:m / z 409.4[M+H] + ,C 20 H 17 BrN4O(408.06).
[0047] Example 4: Preparation of 4-((4-(2,6-dimethyl-4-(phenoxymethyl)phenoxy)pyrimidin-2-yl)amino)benzonitrile (I-1).
[0048] Weigh intermediate 6 (0.25mmol), phenol (0.30mmol), KOH (0.30mmol) and potassium iodide (0.30mmol), mix in 10mL acetonitrile, and heat under reflux at 80℃ for 4h. After the reaction is complete by TLC, evaporate the solvent under reduced pressure, add 20ml saturated brine, and extract with ethyl acetate (3×20mL). Collect the organic phase, dry over anhydrous sodium sulfate, filter and concentrate. Rapid column chromatography separates I-1 (dichloromethane / methanol system).
[0049] White solid, yield: 50%, melting point: 179-182℃.
[0050] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.17(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.57(d,J=8.5Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.33(d,J=9 .8Hz,4H,Ph-H),7.09(d,J=8.0Hz,2H,Ph-H),6.97(t,J=7.3Hz,1H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.08(s,2H,CH2),2.09(s,6H,2×CH3). 13 C NMR(100MHz,DMSO-d6)δ168.97,160.76,159.68,158.95,149.60,145.07,134.90,133.11,130.90,13 0.01,129.05,121.24,119.90,118.57,115.13,102.90,99.33,69.39,16.55.ESI-MS:m / z423.17[M+H] + .C 26 H 22 N4O2(422.17).
[0051] Example 5: Preparation of 4-((4-(4-((4-cyanophenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-2).
[0052] The operation is the same as above, except that 4-hydroxybenzonitrile is used, white solid, yield: 62%, melting point: 202-205°C.
[0053] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.09(s,1H,NH),8.40(d,J=5.6Hz,1H,C6-pyrimidine-H),7.76-7.71(m,2H,Ph-H),7.50(d,J=8.6Hz,2H,Ph-H),7.41(d,J =8.6Hz,2H,Ph-H),7.27(s,2H,Ph-H),7.19(d,J=8.7Hz,2H,Ph-H),6.58(d,J=5.6Hz,1H,C5-pyrimidine-H),5.13(s,2H,CH2),2.02(s,6H,2×CH3). 13C NMR(100MHz,DMSO-d6)δ168.93,162.37,160.80,159.67,149.85,145.07,134.71,133.94,133.09, 131.07,129.29,119.91,119.55,118.58,116.27,103.57,102.89,99.33,70.05,16.54.ESI-MS:m / z 448.38[M+H] + .C 27 H 21 N5O2(447.17).
[0054] Example 6: Preparation of 3-((4-((2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzyl)oxy)benzonitrile (I-3).
[0055] The operation is the same as above, except that 3-cyanophenol is used, white solid, yield: 54%, melting point: 199-202°C.
[0056] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.57(d,J=8.5Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.33(d,J=9 .8Hz,4H,Ph-H),7.09(d,J=8.0Hz,2H,Ph-H),6.97(t,J=7.3Hz,1H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.08(s,2H,CH2),2.09(s,6H,2×CH3). 13 C NMR(100MHz,DMSO-d6)δ168.94,160.79,159.67,159.08,149.82,145.07,134.10,133.09,131.36,131.04, 129.31,125.26,121.00,119.92,119.10,118.59,118.03,112.83,102.90,99.33,70.11,16.54.ESI-MS:m / z 448.38[M+H] + .C 27 H 21 N5O2(447.17).
[0057] Example 7: Preparation of 2-((4-((2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzyl)oxy)benzonitrile (I-4).
[0058] The operation is the same as above, except that 2-cyanophenol is used, white solid, yield: 61%, melting point: 198-201°C.
[0059] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.15 (s, 1H, NH), 8.47 (d, J = 5.6Hz, 1H, C6-pyrimidine-H), 7.77 (dd ,J=7.7,1.7Hz,1H,Ph-H),7.70(td,J=8.0,7.5,1.7Hz,1H,Ph-H),7.61(d,J=8.5Hz,2H,Ph-H) ,7.48(d,J=8.6Hz,2H,Ph-H),7.43(d,J=8.6Hz,1H,Ph-H),7.35(s,2H,Ph-H),7.14(t,J=7.6H z,1H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.30(s,2H,CH2),2.11(s,6H,2×CH3). 13 C NMR (100MHz, DMSO-d6) δ168.93,160.72,160.47,159.71,149.73,145.01,135.52,134.30,133.91,133. 17,131.07,128.77,121.84,119.86,118.57,116.88,114.01,103.03,101.35,99.42,70.34.ESI-MS:m / z 448.30[M+H] + .C 27 H 21 N5O2(447.17).
[0060] Example 8: Preparation of 4-((4-(4-((4-methoxyphenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-5).
[0061] The operation is the same as above, except that 4-methoxyphenol is used, white solid, yield: 63%, melting point: 188-191°C.
[0062] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.16(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.58(d,J=8.5Hz,2H,Ph-H),7.51(d,J=8.6Hz,2H,Ph-H),7.30(s,2H,P h-H),7.06–7.00(m,2H,Ph-H),6.92–6.85(m,2H,Ph-H),6.65(d,J=5.6Hz,1H ,C5-pyrimidine-H),5.02(s,2H,CH2),3.71(s,3H,CH3),2.09(s,6H,2×CH3). 13 C NMR(100MHz,DMSO-d6)δ168.98,160.76,159.68,153.97,153.01,149.52,145.08,135.15,133.12, 130.85,128.95,119.91,118.60,116.03,115.10,102.90,99.33,70.00,55.82,16.55.ESI-MS:m / z 453.20[M+H] + .C 27 H 24 N4O3(452.18).
[0063] Example 9: Preparation of 4-((4-(4-((3-methoxyphenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-6).
[0064] The operation is the same as above, except that 3-methoxyphenol is used, white solid, yield: 63%, melting point: 149-152°C.
[0065] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),7.59(d,J=8.5Hz,2H,Ph-H),7.50(d,J=8.6Hz,2H,Ph-H),7.32(s,2H,Ph-H) ,7.22(t,J=8.2Hz,1H,Ph-H),6.71–6.62(m,3H,Ph-H),6.56(dd,J=8.2,2.3Hz, 1H,C5-pyrimidine-H),5.08(s,2H,CH2),3.76(s,3H,CH3),2.10(s,6H,2×CH3). 13C NMR(100MHz,DMSO-d6)δ168.97,161.04,160.75,160.23,159.69,149.59,145.07,134.85,133.12,130.89,130.4 5,129.02,119.90,118.60,107.34,107.06,102.92,101.37,99.33,69.56,55.55,16.55.ESI-MS:m / z453.25[M+H] + .C 27 H 24 N4O3(452.18).
[0066] Example 10: Preparation of 4-((4-(4-((2-methoxyphenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-7).
[0067] The operation is the same as above, except that 2-methoxyphenol is used, white solid, yield: 58%, melting point: 208-211°C.
[0068] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.15 (s, 1H, NH), 8.47 (d, J = 5.7Hz, 1H, C6-pyrimidine-H), 7. 63(d,J=8.3Hz,2H,Ph-H),7.52(d,J=8.5Hz,2H,Ph-H),7.31(s,2H,Ph-H),7.12(d,J=7 .4Hz,1H,Ph-H),7.01(d,J=7.5Hz,1H,Ph-H),6.92(p,J=7.4Hz,2H,Ph-H),6.65(d,J=5 .7Hz,1H,C5-pyrimidine-H),5.06(s,2H,CH2),3.78(s,3H,CH3),2.10(s,6H,2×CH3). 13 C NMR(100MHz,DMSO-d6)δ168.99,160.65,159.72,149.72,149.50,148.45,145.05,135.02,133.19,130.81, 129.05,121.71,121.08,119.89,118.66,114.20,112.62,102.99,99.47,70.27,55.95,16.58.ESI-MS:m / z 453.32[M+H] + .C 27 H 24 N4O3(452.18).
[0069] Example 11: Preparation of 4-((4-(4-((4-(hydroxymethyl)phenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-8).
[0070] The operation is the same as above, except that p-hydroxybenzyl alcohol is used, white solid, yield: 50%, melting point: 209-212°C.
[0071] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.16 (s, 1H, NH), 8.46 (d, J = 5.6Hz, 1H, C6-pyrimidine-H) ,7.57(d,J=8.6Hz,2H,Ph-H),7.51(d,J=8.6Hz,2H,Ph-H),7.32(s,2H,Ph-H),7.26 (d,J=8.1Hz,2H,Ph-H),7.04(d,J=8.2Hz,2H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyri midine-H),5.07(s,3H,CH2,OH),4.43(d,J=5.7Hz,2H,CH2,),2.09(s,6H,2×CH3). 13 CNMR(100MHz,DMSO-d6)δ168.98,160.77,159.68,157.87,149.58,145.08,135.31,134.97,133.11 ,130.88,129.05,128.42,119.91,118.59,114.73,102.90,99.33,69.53,63.02,16.55.ESI-MS:m / z 451.54[MH] - .C 27 H 24 N4O3(452.18).
[0072] Example 12: Preparation of 4-((4-(4-((3-(hydroxymethyl)phenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-9).
[0073] The operation is the same as above, except that 3-hydroxybenzyl alcohol is used, white solid, yield: 50%, melting point: 147-150°C.
[0074] Spectral data: 1H NMR(400MHz,DMSO-d6)δ10.17(s,1H,NH),8.47(d,J=5.7Hz,1H,C6-pyrimidine-H),7.59(d, J=8.7Hz,2H,Ph-H),7.51(d,J=8.4Hz,2H,Ph-H),7.32(s,2H,Ph-H),7.27(t,J=7.9Hz,1H,Ph- H),7.05(s,1H,Ph-H),6.94(d,J=7.8Hz,2H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H) ,5.19(t,J=5.8Hz,1H,OH),5.08(s,2H,CH2),4.51(d,J=5.5Hz,2H,CH2),2.09(s,6H,2×CH3). 13 C NMR(100MHz,DMSO-d6)δ168.98,160.76,159.68,158.94,149.57,145.08,144.86,134.96,133.13,130.88, 129.63,129.05,119.91,119.29,118.60,113.29,113.08,102.91,99.35,69.42,63.24,16.56.ESI-MS:m / z 453.48[M+H] + .C 27 H 24 N4O3(452.18).
[0075] Example 13: Preparation of 4-((4-(4-((2-(hydroxymethyl)phenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-10).
[0076] The operation is the same as above, except that salicyl alcohol is used, white solid, yield: 45%, melting point: 179-182°C.
[0077] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.21–10.16(m,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.62(d,J= 8.5Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.43(dd,J=7.5,1.7Hz,1H,Ph-H),7.31(s,2H,Ph-H),7. 22(td,J=7.8,1.8Hz,1H,Ph-H),7.08(d,J=8.2Hz,1H,Ph-H),6.97(t,J=7.4Hz,1H,Ph-H),6.64(d,J=5 .6Hz,1H,C5-pyrimidine-H),5.34(s,1H,OH),5.14(s,2H,CH2),4.60(s,2H,CH2),2.10(s,6H,2×CH3). 13 CNMR(100MHz,DMSO-d6)δ169.04,160.47,159.54,155.60,149.33,144.99,135.31,133.14,131.24,130.82 ,128.25,128.01,127.63,120.92,119.84,118.68,112.08,103.03,99.43,69.30,58.43,16.64.ESI-MS:m / z 453.38[M+H] + .C 27 H 24 N4O3(452.18).
[0078] Example 14: Preparation of 4-((4-(2,6-dimethyl-4-((pyridin-3-yloxy)methyl)phenoxy)pyrimidin-2-yl)amino)benzonitrile (I-11).
[0079] The operation is the same as above, except that 3-hydroxypyridine is used, white solid, yield: 47%, melting point: 237-240°C.
[0080] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.16 (s, 1H, NH), 8.46 (d, J = 5.6Hz, 1H, C6-pyrimidine-H), 7.66 (t, J = 2. 3Hz,1H,pyridine-H),7.62(d,J=5.5Hz,1H,Ph-H),7.54(d,J=8.5Hz,2H,Ph-H),7.39(s,2H,Ph-H ),7.38(d,J=8.7Hz,2H,Ph-H),7.32(dd,J=9.0,5.4Hz,1H,pyridine-H),6.96(dd,J=8.9,2.7Hz, 1H,pyrimidine-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.38(s,2H,CH2),2.08(s,6H,2×CH3). 13 C NMR(100MHz,DMSO-d6)δ168.79,160.82,159.65,150.23,144.99,134.09,133.33,133.26, 133.04,131.54,129.48,127.51,119.80,118.48,102.93,99.39,62.23,16.58.ESI-MS:m / z 424.10[M+H] + .C 25 H 21 N5O2(423.17).
[0081] Example 15: Preparation of 3-((4-((2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzyl)oxy)picolinonitrile (I-12).
[0082] The operation is the same as above, except that 2-cyano-3-hydroxypyridine is used, white solid, yield: 41%, melting point: 245-248°C.
[0083] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.14 (s, 1H, NH), 8.47 (d, J = 5.6Hz, 1H, C6-pyrimidine-H), 8.36 (d,J=4.5Hz,1H,pyridine-H),7.97(d,J=8.7Hz,1H,pyridine-H),7.76(dd,J=8.8,4.5H z,1H,pyridine-H),7.61(d,J=8.5Hz,2H,Ph-H),7.50(d,J=8.5Hz,2H,Ph-H),7.36(s,2H ,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.36(s,2H,CH2),2.11(s,6H,2×CH3). 13 C NMR (100MHz, DMSO-d6) δ168.91,160.75,159.70,158.34,149.91,145.00,143.70,133.33,133.17,131. 18,129.48,128.99,122.69,122.61,119.85,118.58,115.95,103.03,99.41,70.77,16.63.ESI-MS:m / z 447.24[MH] - .C 26 H 20 N6O2(448.16).
[0084] Example 16: Preparation of 5-((4-((2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzyl)oxy)nicotinonitrile (I-13).
[0085] The operation is the same as above, except that 3-cyano-5-hydroxypyridine is used, white solid, yield: 52%, melting point: 195-198°C.
[0086] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.09 (s, 1H, NH), 8.64 (d, J = 2.9Hz, 1H, pyridine-H), 8.58 (d, J=1.5Hz,1H,pyrimidine-H),8.40(d,J=5.6Hz,1H,C6-pyrimidine-H),8.05(t,J=2.3Hz, 1H,pyridine-H),7.51(d,J=8.5Hz,2H,Ph-H),7.42(d,J=8.6Hz,2H,Ph-H),7.28(s,2H, Ph-H), 6.59 (d, J=5.6Hz, 1H, C5-pyrimidine-H), 5.17 (s, 2H, CH2), 2.03 (s, 6H, 2×CH3). 13 C NMR (100MHz, DMSO-d6) δ168.91,160.83,159.67,154.64,149.98,145.06,145.01,143.13,133.54,133. 10,131.15,129.49,124.45,119.92,118.60,117.21,109.75,102.91,99.34,70.61,16.54.ESI-MS:m / z 447.27[MH] + .C 26 H 20 N6O2(448.16).
[0087] Example 17: 4-((4-(4-(((6-fluoropyridin-3-yl)oxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-14).
[0088] The operation is the same as above, except that 2-fluoro-5-hydroxypyridine is used, white solid, yield: 61%, melting point: 185-188°C.
[0089] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.16 (s, 1H, NH), 8.47 (d, J = 5.6Hz, 1H, C6-pyrimidine-H), 8.04 (dd ,J=3.1,1.8Hz,1H,pyridine-H),7.74(ddd,J=9.4,6.7,3.1Hz,1H,pyridine-H),7.58(d,J=8 .6Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.34(s,2H,Ph-H),7.16(dd,J=8.9,3.4Hz,1H,p pyrimidine-H), 6.65 (d, J=5.6Hz, 1H, C5-pyrimidine-H), 5.17 (s, 2H, CH2), 2.10 (s, 6H, 2×CH3). 13 C NMR (100MHz, DMSO-d6) δ168.93,160.80,159.67,158.86,156.58,153.59,153.55,149.81,145.06,134.15,133.86,133. 70,133.11,131.04,129.26,128.98,128.90,119.91,118.59,110.50,110.10,102.89,99.32,70.73,16.54.ESI-MS:m / z 442.61[M+H] + .C 25 H 20 FN5O2(441.16).
[0090] Example 18: Preparation of 4-((4-(2,6-dimethyl-4-((4-nitrophenoxy)methyl)phenoxy)pyrimidin-2-yl)amino)benzonitrile (I-15).
[0091] The operation is the same as above, except that 4-nitrophenol is used, white solid, yield: 71%, melting point: 233-236°C.
[0092] Spectral data: 1H NMR (400MHz, DMSO-d6) δ10.20(s,1H,NH),8.48(d,J=5.6Hz,1H,C6-pyrimidine-H),8.25(d,J=8.8Hz,2H,Ph-H),7.59(d,J=8.6Hz,2H,Ph-H),7.49(d ,J=8.5Hz,2H,Ph-H),7.37(s,2H,Ph-H),7.31(d,J=8.9Hz,2H,Ph-H),6.67(d,J=5.6Hz,1H,C5-pyrimidine-H),5.27(s,2H,CH2),2.11(s,6H,2×CH3). 13 C NMR (100MHz, DMSO-d6) δ168.91,164.18,160.80,159.66,149.93,145.08,141.45,133.73,133. 06,131.11,129.33,126.36,119.92,118.57,115.71,102.86,99.30,70.56,16.53.ESI-MS:m / z 468.19[M+H] + .C 26 H 21 N5O4(467.16).
[0093] Example 19: Preparation of tert-butyl (4-((4-((2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzyl)oxy)phenyl)carbamate (I-16).
[0094] The operation is the same as above, except that 4-(BOC-amino)phenol is used, white solid, yield: 73%, melting point: 184-187°C.
[0095] Spectral data: 1 H NMR(400MHz,DMSO-d6)δ10.15(s,1H,NH),9.14(s,1H,NH),8.46(d,J=5.7Hz,1H,C6 -pyrimidine-H),7.58(d,J=8.7Hz,2H,Ph-H),7.51(d,J=8.7Hz,2H,Ph-H),7.38(d ,J=8.5Hz,2H,Ph-H),7.31(s,2H,Ph-H),7.02–6.96(m,2H,Ph-H),6.64(d,J=5.7Hz ,1H,C5-pyrimidine-H),5.01(s,2H,CH2),2.09(s,6H,2×CH3),1.47(s,9H,3×CH3). 13C NMR(100MHz,DMSO-d6)δ168.97,160.77,159.67,154.19,153.40,149.57,145.07,134.99,133.34,133.12 ,130.85,129.14,120.11,119.90,118.60,115.14,102.90,99.32,79.13,69.75,28.65,16.54.ESI-MS:m / z 538.16[M+H] + .C 31 H 31 N5O4(537.24).
[0096] Example 20: Preparation of 4-((4-(4-((4-aminophenoxy)methyl)-2,6-dimethylphenoxy)pyrimidin-2-yl)amino)benzonitrile (I-17).
[0097] Weigh compound I-16 (0.2 g, 0.37 mmol) and dissolve it in 5 mL of dichloromethane, add 2 mL of trifluoroacetic acid, and stir at room temperature for 3 h. After TLC detection, add saturated sodium bicarbonate solution to the reaction solution until the pH is 8-9. Extract with dichloromethane (3×20 mL), dry the organic phase with anhydrous sodium sulfate, filter and concentrate, and separate I-17 by rapid column chromatography.
[0098] White solid, yield: 65%, melting point: 241-244℃.
[0099] Spectral data: 1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H,NH),9.35(s,2H,NH2),8.47(d,J=5.7Hz,1H,C6-pyrimidine-H),7.56(d,J=8.7Hz,2H,Ph-H),7.50(d,J=8.6Hz,2H,Ph-H) ,7.32(s,2H,Ph-H),7.21(d,J=8.5Hz,2H,Ph-H),7.14(d,J=8.5Hz,2H,Ph-H),6 .66(d,J=5.7Hz,1H,C5-pyrimidine-H),5.09(s,2H,CH2),2.09(s,6H,2×CH3). 13C NMR(100MHz,DMSO-d6)δ168.95,160.83,159.65,157.18,149.71,145.09,134.59,133.11,130.96,12 9.20,127.78,123.35,119.95,118.57,116.11,102.85,99.31,69.97,16.54.ESI-MS:m / z438.57[M+H] + .C 26 H 23 N5O2(437.19).
[0100] Example 21: In vitro anti-HIV activity test of target compounds
[0101] (1) Test principle: MTT is Thiazole Blue. Its detection principle is that the succinate dehydrogenase in the mitochondria of living cells reduces MTT to water-insoluble blue-purple crystalline formazan and deposits it in the cells, while dead cells do not have this function. Formazan can be dissolved by dimethyl sulfoxide (DMSO), and the color depth of the solution is proportional to the amount of formazan contained in the cells. The absorbance of the final solution at a certain wavelength is measured with an enzyme-labeled instrument, and the absorbance value can indirectly reflect the number of living cells.
[73] .
[0102] (2) Experimental materials:
[0103] ①HIV-1 wild-type strain (IIIB), HIV-2 strain (ROD), HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A, and RES056), and MT-4 cells: all provided by the Rega Institute, University of Leuven, Belgium.
[0104] ②MTT: purchased from Acros Organics, Geel, Belgium.
[0105] ③Sample treatment: Before testing, dissolve the sample to be tested in DMSO solution to a suitable concentration, and then dilute it 5 times with double distilled water, with 5 dilutions each.
[0106] ④Positive control drugs: zidovudine (AZT), lamivudine (3TC), nevirapine (NVP), efavirenz (EFV) and etravirine (ETR).
[0107] (3) Experimental methods:
[0108] 50 μL of 1×10 4MT-4 cell culture medium, 20 μL HIV-infected MT-4 cell suspension or blank culture medium (uninfected cells, used for toxicity determination), different concentrations of test compound solutions or positive control drugs (3 replicates for each concentration). The cells were cultured for 5 days in a 5% CO2 atmosphere, 37°C, and relative humidity ≥95%. Then 20 mL of MTT solution (5 mg / mL) was added to each well. After 2 hours of culture, 150 μL of DMSO solution was added, and the absorbance of the reaction solution was measured using an enzyme reader (measurement wavelength 540 nm, reference wavelength 690 nm). The concentration of the compound that protects 50% of MT-4 cells from pathological changes is the in vitro anti-HIV activity of the target compound (EC 50 The concentration of a compound that causes 50% of normal cells not infected with HIV to die is called cytotoxicity (CC 50 ), and the selectivity index (SI = CC) was calculated based on the two 50 / EC 50 ).
[0109] (4) Experimental results:
[0110] According to the above method, the synthesized representative compounds were screened for activity at the cellular level against wild-type HIV-1 (IIIB) and HIV-2 (ROD), single mutant strains L100I, K103N, Y181C, Y188L, E138K, and double mutant strains F227L / V106A, RES056 (K103N / Y181C). The results are shown in Tables 1 and 2.
[0111] Table 1. Anti-HIV-1IIIB, ROD activity and cytotoxicity test results of compounds
[0112]
[0113]
[0114] a EC 50 : The concentration of compound that protects 50% of MT-4 cells from pathological changes. b CC 50 : The concentration of compound that causes 50% of normal cells not infected with HIV to die. c SI: Selectivity Index, CC 50 / EC 50 .
[0115] Table 2. Test results of the activity of compounds against HIV-1 mutants
[0116]
[0117]
[0118] a EC 50 : The concentration of compound that protects 50% of MT-4 cells from pathological changes.
[0119] Conclusion: The results of cell-level activity showed that all compounds had inhibitory activity against wild-type HIV-1, among which I-2 (EC 50 =7.6 nM), I-4 (EC 50 =7.8 nM) and I-12 (EC 50 =7.8nM) was the most active, superior to the positive drug AZT (EC 50 =0.127 μM) and NVP (EC 50 =0.023 μM), and I-2 (CC 50 >279.33 μM) had low cytotoxicity. For the HIV-1 mutants tested, most compounds showed inhibitory activity of tens to hundreds of nanomolar against K103N and E138K, especially for the K103N mutant, among which compound I-2 (EC 50 =28 nM), I-12 (EC 50 =35 nM) and I-13 (EC 50 =28nM) is more prominent and better than NVP (EC 50 =7.495 μM) and EFV (EC 50 =95 nM). For the E138K mutant, I-2 (EC 50 =44 nM) and I-12 (EC 50 =46nM) and were superior to NVP (EC 50 =149 nM). Therefore, this type of diaryl pyrimidine derivatives has the value of further research and development and can be used as a lead compound against HIV-1.
Claims
1. A diaryl pyrimidine compound containing an ether bond, or a pharmaceutically acceptable salt thereof, characterized in that: It has the structure shown in general formula I: In the above general formula: R1 and R2 are independently: H, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, C 2- C6 alkenyl, trifluoromethyl, amino, hydroxyl or cyanovinyl; R3 is a substituted or unsubstituted benzene ring, a substituted or unsubstituted pyridine ring; the substituent is selected from methoxy, nitro, cyano, amino, BOC-amino, F, Cl, Br or hydroxymethyl.
2. The diaryl pyrimidine compound containing an ether bond according to claim 1, characterized in that: The compound is one of the following:
3. Use of the diaryl pyrimidine compound containing an ether bond as claimed in any one of claims 1 to 2 in the preparation of drugs for treating and preventing human immunodeficiency virus.
4. A pharmaceutical composition comprising the ether-bonded diaryl pyrimidine compound according to any one of claims 1 to 2 and one or more pharmaceutically acceptable carriers or excipients.
Citation Information
Patent Citations
Pyrimidine derivatives for the prevention of HIV infection
CN102151270A
Resorcarenes-polysubstitution pyrimidine derivative as well as preparation method and application of derivative
CN103483272A
Diaryl pyridine derivative as well as preparation method and application thereof
CN104876860A
Substituted diarylpyrimidine derivative as well as preparation method and application thereof
CN106831605A
Diaryl thienopyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof
CN106866699A
